What is the prevalence of Acrodermatitis Enteropathica?

Acrodermatitis enteropathica is an ultra-rare genetic disorder with an estimated prevalence of approximately 1 in 500,000 people globally. Because many cases are likely misdiagnosed as severe dermatitis or nutritional deficiencies, the true prevalence of acrodermatitis enteropathica is believed to be higher than currently reported figures.

Is acrodermatitis enteropathica considered rare?

Yes, acrodermatitis enteropathica is classified as an ultra-rare autosomal recessive disorder. Due to its rarity, epidemiological data is limited. While the prevalence is cited at roughly 1 in 500,000, the actual incidence is difficult to track because the condition is often under-recognized by clinicians who may mistake its symptoms for other inflammatory skin conditions.

What are the demographic patterns of acrodermatitis enteropathica?

The condition does not show a predilection for specific ethnic groups or geographic regions, appearing globally across diverse populations. Regarding patient demographics, acrodermatitis enteropathica typically presents with the following characteristics:

• Gender Distribution: Both males and females are affected equally, as the underlying mutation in the SLC39A4 gene is located on an autosome.


• Age of Onset: Symptoms most commonly emerge in early infancy, particularly shortly after weaning from breast milk to formula or solid foods, though delayed onset can occur.


• Clinical Recognition: The rarity of acrodermatitis enteropathica often leads to significant diagnostic delays, which can obscure accurate prevalence and incidence reporting.

Why is accurate data for acrodermatitis enteropathica limited?

Data gaps exist because acrodermatitis enteropathica is frequently misdiagnosed as atopic dermatitis, psoriasis, or acrodermatitis of other origins. Our DiseaseMaps.org community currently includes one member living with this condition; while this represents a small sample, it underscores the isolation often felt by patients with such a rare diagnosis. Real-world insights from platforms like DiseaseMaps.org help bridge the gap between clinical literature and the lived experience of those managing acrodermatitis enteropathica.

Next steps

• Consult a metabolic specialist or a pediatric dermatologist to confirm a diagnosis via genetic testing for SLC39A4 mutations.


• Monitor serum zinc levels closely under the guidance of a medical professional.


• Join specialized rare disease communities, such as the one at DiseaseMaps.org, to connect with others navigating the complexities of acrodermatitis enteropathica.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• Orphanet: Acrodermatitis enteropathica (ORPHA:179)


• NIH Genetic and Rare Diseases Information Center (GARD)


• OMIM (Online Mendelian Inheritance in Man): Entry #201100


• PubMed/NCBI: Review of zinc deficiency and genetic acrodermatitis enteropathica